Previous Article | Next Article 
Journal of Virology, May 2000, p. 4795-4806, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Identification of Critical Amino Acid Residues in Human
Immunodeficiency Virus Type 1 IN Required for Efficient Proviral
DNA Formation at Steps prior to Integration in Dividing and
Nondividing Cells
Naomi
Tsurutani,1,2
Makoto
Kubo,1,3
Yosuke
Maeda,4
Takashi
Ohashi,1
Naoki
Yamamoto,2
Mari
Kannagi,1,3 and
Takao
Masuda1,*
Department of Immunotherapeutics, Medical
Research Division,1 and Department of
Microbiology and Molecular Virology,2 School
of Medicine, Tokyo Medical and Dental University, Tokyo,
CREST, Japan Science and Technology Corporation,
Saitama,3 and Department of Biodefense
and Medical Virology, Kumamoto University School of Medicine,
Kumamoto,4 Japan
Received 18 October 1999/Accepted 11 February 2000
 |
ABSTRACT |
Human immunodeficiency virus type 1 integrase (HIV-1 IN) is thought
to have several putative roles at steps prior to integration, such as
reverse transcription and nuclear transport of the preintegration complex (PIC). Here, we investigated new functional aspects of HIV-1 IN
in the context of the viral replication cycle through point mutagenesis
of Ser, Thr, Tyr, Lys, and Arg residues conserved in IN, some of which
are located at possible phosphorylation sites. Our results showed that
mutations of these Ser or Thr residues had no effect on reverse
transcription and nuclear transport of PIC but had a slight effect on
integration. Of note, mutations in the conserved KRK motif (amino acids
186 to 189), proposed previously as a putative nuclear localization
signal (NLS) of HIV-1 IN, did not affect the karyophilic property of
HIV-1 IN as shown by using a green fluorescent protein fusion protein
expression system. Instead, these KRK mutations resulted in an almost
complete lack of viral gene expression due to the failure to complete
reverse transcription. This defect was complemented by supplying
wild-type IN in trans, suggesting a
trans-acting function of the KRK motif of IN in reverse
transcription. Mutation at the conserved Tyr 143 (Y143G) resulted in
partial impairment of completion of reverse transcription in
monocyte-derived macrophages (MDM) but not in rhabdomyosarcoma cells.
Similar effects were obtained by introducing a stop codon in the
vpr gene (
Vpr), and additive effects of both mutations
(Y143G plus
Vpr) were observed. In addition, these mutants did not
produce two-long terminal repeat DNA, a surrogate marker for nuclear
entry, in MDM. Thus, the possible impairment of Y143G might occur
during the nuclear transport of the PIC. Taken together, our results
identified new functional aspects of the conserved residues in HIV-1
IN: i) the KRK motif might have a role in efficient reverse
transcription in both dividing and nondividing cells but not in the NLS
function; ii) Y143 might be an important residue for maintaining
efficient proviral DNA formation in nondividing cells.
 |
INTRODUCTION |
Retroviruses establish a proviral
state in which a double-stranded DNA copy of the viral genomic RNA is
integrated into the host genome in a stable manner, through several
steps following binding and entry into the target cell. These early
events include uncoating, reverse transcription, nuclear transport of
the viral genome, and integration. The viral enzyme integrase (IN) is
encoded by the pol gene and the attachment (att)
site located at the U3 and U5 termini of the viral DNA and is required
for integration, which is the last event (6, 14, 43, 47, 53, 56,
57, 61, 66, 74). The detailed mechanism of retroviral integration has been elucidated from in vitro studies using recombinant IN protein
and a synthetic DNA substrate mimicking the viral att sites.
These studies, using in vitro assays, have contributed much information
toward the currently accepted mechanism of retroviral integration
(reviewed in references 34, 42, and
75). Mutational and structural studies of human
immunodeficiency virus type 1 (HIV-1) IN have identified three
functional domains: a central catalytic core domain, an N-terminal zinc
binding domain, and a C-terminal nonspecific DNA binding domain. The
core domain contains the highly conserved D,D35E motif, which is
directly involved in the catalytic activities of IN (7, 23, 46,
48). The N-terminal domain contains a highly conserved HHCC
motif, which binds to zinc. Through a tetrahedral attachment to the
HHCC motif, zinc enhances both multimerization and enzymatic activities
of HIV-1 IN in vitro (5, 8, 21, 79). The C terminus,
consisting of a structure that closely resembles Src homology 3 domains, possesses sequence- and metal ion-independent DNA binding
activity (20, 51). Each domain has been demonstrated to form
a dimer or higher multimerization state of IN (8, 19, 20),
which might be required for its full activity (13, 21, 22, 66, 70,
73).
Genetic analysis of HIV-1 IN has demonstrated multiple effects of
mutations at steps distinct from integration. These steps include
correct viral particle formation (24, 59), uncoating (54, 59), and reverse transcription (49, 54).
During the early events of the infection cycle, prior to integration,
around 50-100 protomers of IN exist as one of the major components of the preintegration complex (PIC). This is composed of the viral genome,
the matrix protein (MA), viral protein R (Vpr), and other viral and
host proteins (3, 4, 26, 27). A small number of protomers of
IN are thought to be sufficient for the integration reaction. The
multiple effects of IN mutations suggest that IN has roles during the
early events prior to integration, such as reverse transcription and
nuclear transport of the PIC. Several important aspects of these
putative roles in the context of the viral replication cycle still
remain to be determined. Cellular or viral cofactors may participate in
the steps leading to integration in vivo. The host factors HMG-I(Y)
(26, 36), Ini1 (integrase interactor 1) (40, 41),
and BAF (barrier-to-autointegration factor) (12) are
associated with IN and stimulate integration activity. Recently, it has
been reported that DNA-dependent protein kinase is involved in the
completion of the integration process (18). On the other
hand, HIV-1 IN has been shown to interact with importin
alpha-karyopherin, the cellular nuclear localization signal (NLS)
receptor, and to facilitate nuclear transport of the PIC
(31). Transport of the PIC from the cytoplasm into the nucleus is thought to be a key step in establishing proviral DNA formation of HIV-1 in nondividing cells such as macrophages (reviewed in reference 3). It has been reported that
phosphorylation of a Tyr residue on MA governs HIV nuclear import
(32). However, results pertaining to MA function in the
nuclear import process are controversial (29, 30). The NLS
presented in MA might be weak and insufficient to ensure effective
import of the PIC (4, 58). In addition, Vpr is thought to
act as a key regulator of nuclear import of HIV-1, enhancing the
affinity of the putative NLS to the host nuclear pore complex (1,
2, 15, 28, 30, 35, 52, 64). These observations suggest that
proteins other than MA, most probably IN, possess the NLS, enabling
HIV-1 to infect nondividing cells with Vpr helper function.
Phosphorylation of viral proteins also plays an important role in the
regulation of the viral life cycle. Identification of the
virion-associated kinase and the mitogen-activated protein kinase
(known as ERK or MAPK) suggested that an MAPK signal transduction pathway in the host cell might regulate an early step in HIV-1 infection (38). The phosphorylation status of IN after
infection and its role(s) during early events in the retroviral
infection cycle are poorly understood. In this study, we generated a
series of HIV-1 IN mutant clones carrying single-amino acid
substitutions at conserved Ser, Thr, or Tyr residues; some of them are
located at a possible motif for phosphorylation by casein kinase II
(CK-II) or protein kinase C (PKC). Furthermore, we introduced point or deletion mutations in the conserved Lys and Arg residues, reported to
be the putative NLS of HIV-1 IN (31). Genetic analysis of HIV-1 IN mutants in the present study showed that in the context of the
viral infection cycle, the KRK motif in HIV-1 IN has a trans-acting function which is important for the completion
of reverse transcription in both dividing and nondividing cells. In
addition, Y143 may be a key residue for efficient proviral formation in
nondividing cells.
 |
MATERIALS AND METHODS |
Construction of mutants.
DNA fragments for mutagenesis of
HIV-1 IN were derived from the HIV-1 pNL43luc
env vector (54,
62) in which the env gene is defective, allowing the
formation of pseudotypes, and the nef gene is replaced with
the firefly luciferase (Luc) gene. For mutagenesis of Thr and Tyr
residues (T66A, T93A, T125A, and Y143G), a 1.6-kb fragment of the
pNL43luc
env vector, spanning the KpnI and SalI sites (nucleotides [nt] 4154 to 5785), was subcloned into pBluescript SK(+) (Stratagene, Calif.) (pSKnlK/S). To introduce mutations at each
residue, four mutagenic primers were designed to span the
NsiI and AflII sites (nt 4377 to 4743). Products
amplified by PCR with each mutagenic primer pair were digested with
NsiI and AflII. Then, the mutant fragments were
ligated to NsiI-AflII-digested pSKnlK/S. After
confirmation of mutation by DNA sequence analysis, KpnI-SalI fragments (nt 4154 to 5785) containing
each mutation were ligated to the fragment spanning nt 1507 to 4154 to
generate the 4.2-kb SpeI-SalI fragment (nt 1507 to 5785). The SpeI/SalI fragments, containing
each mutation, were inserted back into the pNL43luc
env vector. For
mutagenesis of the Ser residues (S195A and S283A) or Lys and Arg
residues (K186Q,
KRK, and K211N), mutagenic primers were designed to
span the AflII and NdeI sites (nt 4743 to 5172)
of the pNL43luc
env vector. The products amplified by PCR using each
mutagenic primer pair, were subcloned into an
AflII-NdeI-digested pGEM5-5Zf(+) vector (Promega,
Madison, Wis.), containing pNL43luc
env (nt 1507 to 5122 [SpeI-NdeI fragment]). The 3.6-kb fragment of pNL43luc
env spanning the SpeI and NdeI sites
(nt 1505 to 5122), which contained each mutation, were inserted back
into the pNL43luc
env vector. DNA sequence analysis showed that the
K211N mutant fragment contained an additional mutation of G to A at nt
4874, resulting in a Gly-to-Arg substitution at amino acid 189. We
therefore termed this mutant K211N G/R. For preparation of the
Vpr-defective clone (
Vpr), a stop codon (TAA) was introduced in the
vpr open reading frame at nt 5624 to 5626 using mutagenic
primers 5'-TAAGCTAACTTAAGAGTGAA-3' (nt 5624 to 5645). This
mutation site was 7 nt downstream to the end of the vif open
reading frame. To generate the double mutant, Y143G&
Vpr, the
NdeI-SalI fragment (nt 5124 to 5785) which
contained the
Vpr mutation was replaced with the corresponding
region of the SpeI-SalI pBluescript SK(+) vector
containing the Y143G mutation. The SpeI-SalI
fragment containing both mutations was inserted back into the
pNL43luc
env vector. To prepare the eukaryotic expression vector for
HIV-1 IN fused to green fluorescent protein (GFP), the entire coding
region of HIV-1 IN was amplified by PCR and inserted into the
pCMX-SAH/Y145F vector (kindly provided by Kazuhiko Umesono and Hidesato
Ogawa, Kyoto University, Kyoto, Japan) at the SalI and
BamHI sites. Primers used for amplification of HIV-1 IN were
as follows: GFPIN-sense
(5'-ACGCGTCGACGTCGGCCATAGCGGCCTTTTTAGATGGAATAGAT-3') and
GFPIN-antisense (5'-CGCGGATCCGCGTTAATCCTCATCCTGTCTACT-3'). Similarly, IN-coding regions carrying each mutation were
amplified by PCR using each mutant plasmid (pNL43luc
env) as a
template. The amplified region and cloning junctions were confirmed by
DNA sequencing.
Cell culture and isolation of human MDMs and PBLs.
COS,
human rhabdomyosarcoma (RD), and HeLa cells were cultured in
Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum. Human monocyte-derived macrophages (MDMs) and peripheral
blood lymphocytes (PBLs) were obtained from peripheral blood. Briefly,
peripheral blood was obtained from the buffy coats of healthy,
HIV-seronegative blood donors, and peripheral blood mononuclear cells
were separated over a Ficoll-Hypaque gradient (Ficoll-Paque PLUS;
Amersham, Pharmacia Biotech, Tokyo, Japan). Peripheral blood
mononuclear cell suspensions were incubated for adhesion onto the
plastic of a tissue culture dish in RPMI 1640 (GIBCO BRL, Long Island,
N.Y.) containing 10% human AB serum (Sigma, St. Louis, Mo.) for 2 h. Nonadherent cells (PBLs) were then stimulated with 1%
phytohemagglutinin (Difco Laboratories, Detroit, Mich.). These cells
were grown in RPMI 1640 medium containing 2 ng of recombinant
interleukin 2 (Shionogi, Osaka, Japan) per ml and 10% fetal bovine
serum. Adherent cells were detached with Cell Dissociation Solution
(Sigma) and cultured in RPMI 1640 medium, supplemented with 10% human
AB serum. The cells were >98% macrophages as judged by
fluorescence-activated cell sorter analysis using an anti CD14
monoclonal antibody (DAKO, Kyoto, Japan) and nonspecific esterase activity.
Virus preparation and infection.
Pseudotype viruses were
generated by cotransfection of COS cells with the pNL43luc
env
vector, containing each IN mutation, and an amphotropic Moloney murine
leukemia virus (MuLV) envelope expression vector (pJD-1) or a
macrophage-tropic HIV envelope expression vector (pJR-FL), using
Lipofectamine (GIBCO BRL). The culture supernatants (5 ml) of the
transfected COS cells were harvested 48 h posttransfection,
filtered through 0.45-µm-pore-size filters, and used as virus
preparations. Each virus preparation was treated with DNase I (40 µg/ml; Worthington) in the presence of 10 mM MgCl2 at
37°C for 1 h to avoid DNA contamination. An aliquot of each
virus preparation was incubated at 65°C for 1 h and used as a
heat-inactivated control. To monitor the amount of virus in each
preparation, HIV-1 p24 antigen levels were determined by an enzyme
immunoassay system (EIA-II; Abbott Diagnostika, Wiesbaden-Delkengeim, Germany). To monitor viral gene expression from each plasmid vector, luciferase activity in transfected COS cells was also measured. At
48 h posttransfection, COS cells were lysed with 1 ml of 1× luciferase lysis buffer (Promega). One microliter of each cell lysate
was subjected to the luciferase assay. RD cells (5 × 104), MDMs (5 × 105) or PBLs (1 × 106) were infected with an aliquot (1 ml) of DNase-treated
virus. The infection proceeded in the presence of Polybrene (10 µg/ml) at 37°C. After incubation for 3 h, the viruses were
removed and the cells were overlaid with fresh media and incubated at
37°C.
Luciferase activity.
For luciferase analysis, infected cells
were harvested at 4 days postinfection. The total cell pellets from
each well were washed twice with phosphate-buffered saline (PBS) and
lysed with 200 µl (RD), 150 µl (MDM) or 100 µl (PBL) of 1×
luciferase lysis buffer (Promega). Ten microliters of each cell lysate
was subjected to the luciferase assay.
Analysis of HIV-1 DNA synthesis and formation of two-LTR
circles.
Total cells were harvested from each well at 2 and 6 days
postinfection for RD cells and harvested from each well at 3 days post-infection for MDMs. After washing with PBS, nucleic acids were
extracted as described elsewhere (78). Briefly, cells were disrupted in urea lysis buffer (4.7 M urea, 1.3%, sodium dodecyl sulfate [SDS], 0.23 M NaCl, 0.67 mM EDTA [pH 8.0], 6.7 mM Tris-HCl [pH 8.0]) and subjected to phenol-chloroform extraction and ethanol precipitation. The resulting DNA pellet was resuspended in 50 µl of
water. An aliquot (5 µl) of each sample was subjected to PCR using
primer pairs specific for the R-U5 region of HIV-1 (M667/AA55) or the
R-gag region (M667/M661) as described elsewhere (78). Detection of HIV-1 DNA sequences by each primer pair was performed using 35 cycles of 95°C for 1 min, 65°C for 2 min, and 72°C for 2 min. For HIV-1 DNA standards, 10 to 25,000 copies of linearized HIV-1
JR-CSF DNA were amplified in parallel. Amplified products were resolved
on a 2% agarose gel and stained with Syber-green (FMC Bioproduct,
Rockland, Maine). To normalize the amount of cellular DNA in the
samples, a primer pair complementary to the first exon of the human
-globin gene was used. For detection of human
-globin DNA, 20 cycles of amplification were performed under the same conditions as
those for the HIV-1 DNA amplification. A standard curve for human
-globin DNA was obtained by amplifying known amounts of cellular DNA
from RD or MDM cells in parallel. Quantitative analysis of amplified
products was performed using the Epi-Light UV FA1100 system with a
Luminous Imager (Aisin Cosmos R&D Co.). To further examine the rate of
viral DNA synthesis, real-time quantitative PCR (TaqMan PCR detection;
Perkin-Elmer, Applied Biosystems Division, Foster City, Calif.) was
used. Fluorogenic probes were designed to anneal to the target between
the sense primer and the antisense primer in the R-U5 and the R-gag
region: 5'-TAGTGTGTGCCCGTCTGTTGTGTGAC-3' and
5'-CCGAACAGGGACTTGAAAGCGAAA-3', respectively. To analyze the
two-long terminal repeat (two-LTR) circular DNA in nuclei, PCR was
performed using specific primers as previously described
(24). The amplified products of the two-LTR junction
sequence were further subjected to nested PCR with the following
internal primers: 5'-AATCTCTAGCAGT-3' and
5'-GTCAGTGGATATCTGATCCCTG-3'. The PCR products were detected
as described above.
Western blot analysis.
Viruses were concentrated in an
ultracentrifuge (1 h at 315,000 × g using a Beckman
TLX-100 centrifuge with a TLA-100.4 rotor), and the pellets were
resuspended in PBS. Viral proteins containing approximately 10 ng of
p24 were subjected to SDS-12% polyacrylamide gel electrophoresis.
Following blotting of proteins onto a nitrocellulose membrane (ATTO,
Tokyo, Japan), the membrane was first incubated with antiserum from
AIDS patients (provided by Y. Koyanagi, Tohoku University, Sendai,
Japan) followed by horseradish peroxidase-conjugated anti-human
immunoglobulin. HIV-1 proteins were visualized using an enhanced
chemiluminescence detection system (Amersham, Pharmacia Biotechnology).
Fluorescence microscopy.
HeLa cells (4 × 104) were seeded onto poly-D-lysine-coated
eight-well Culture Slides (Becton Dickinson Labware, Bedford, Mass.) and transfected with the indicated plasmids using Effectene
Transfection Reagent (Qiagen, Hilden, Germany). At 24 h
posttransfection, cells were washed once with PBS and fixed with
acetone for 5 min. After washing with PBS, cells were mounted in 90%
glycerol-50 mM NaHCO3 and covered with a coverslip.
Confocal microscopy was performed with an OLIMPAS BX50 fluorescence
microscope. One representative medial section was mounted using Adobe
Photoshop software.
 |
RESULTS |
Construction of HIV-1 IN mutants.
Genetic analysis of HIV-1 IN
showed that mutations had multiple effects on the viral life cycle,
suggesting that IN might have multiple roles in the early steps
preceding integration. These include uncoating, reverse transcription,
and nuclear transport of the PIC. Recent study has shown that
phosphorylation of viral proteins might be important in regulating
viral infectivity (38). To examine the possible involvement
of HIV-1 IN phosphorylation in the putative functions of IN, we
generated HIV-1 mutants carrying single-amino-acid substitutions at
Ser, Thr, or Tyr residues which are conserved among HIV-1 strains and
HIV-related lentiviruses (Fig. 1). These
included Ser-to-Ala substitutions at position 195 or 283 (S195A or
S283A), Thr-to-Ala substitutions at position 66, 93, or 125 (T66A,
T93A, or T125A), and a Tyr-to-Gly substitution at position 143 (Y143G)
(Fig. 1 and Table 1). Some of these
conserved Ser and Thr residues were located in the possible
phosphorylation motifs, (S/T)XX(D/E) for CK-II (Fig. 1 [shaded
triangle]) and (S/T)X(R/K) for PKC (Fig. 1 [striped triangle]).
These motifs are well conserved among HIV-1 strains, although all are
not completely conserved in other HIV-1-related lentiviruses. In
addition, we generated mutations in the conserved Lys- and Arg-rich
motifs spanning position 186 to 188 and position 211 to 219 of HIV-1 IN
(Fig. 1 [open triangles]), since these motifs are located in the
putative NLS of IN (31) (Fig. 1 [underlined]). The
mutations included a Lys-to-Glu substitution at position 186 (K186Q), a Lys-to-Asn substitution at position 211 with an additional substitution of Gly to Arg at position 189 (K211N G/R), and deletion of the KRK
motif at position 186 to 188 (
KRK). A series of point and deletion
mutations were introduced into the IN gene through site-directed mutagenesis of the SpeI-SalI subgenomic fragments
and reconstruction of the mutations into the HIV-1 pNL43luc
env
vector (54, 62). This vector contained a defective
env gene, allowing formation of HIV-1 (amphotropic)
pseudotypes, and the nef gene was replaced by the firefly
luciferase gene, allowing efficient monitoring of HIV-1 expression. We
prepared a pseudotype virus of each IN mutant by cotransfection of COS
cells with the pNL43luc
env vector carrying each IN mutation and the
amphotropic Moloney MuLV envelope expression vector (pJD-1). All
mutants had comparable levels of p24 in culture supernatants harvested
from transfected COS cells (Fig.
2A) and comparable
levels of luciferase (Luc) activity in cell lysates of transfected COS
cells (Fig. 2B). Thus, mutations had no significant effect on
transfected proviral gene expression or virus release. In order to
verify that the gag-pol polyprotein processing had been completed in
mutant virus particles, we performed a Western blot analysis of viral
proteins contained in virus particles using antiserum from human AIDS
patients. No apparent difference between parental (wild-type [WT])
and mutant viruses was observed in the profiles of viral proteins (Fig.
2C). The profile of viral proteins of each mutant was also verified by
using specific monoclonal antibodies to p24 and reverse transcriptase
(RT) (data not shown). These results showed that none of the mutations
significantly affected the proviral gene expression, virus particle
release, or gag-pol polyprotein processing.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Diagram of the domain structure and mutations of HIV-1
IN. The amino acid sequences of HIV-1 strains (NL43, HXB2, JR-CSF, MN,
and SF2), HIV-2ROD and SIVmac239 were obtained from GenBank. The
accession numbers of HIV-1 NL43, HXB2, JR-CSF, MN, SF2, HIV-2ROD, and
SIVmac239 are M19921, K03455, M38429, M17449, K02007, M15390, and
M33262, respectively. Portions of the central catalytic domain and the
C-terminal domain are shown. Symbols above the sequence are indicated
positions of mutation (shaded triangle, possible site of
phosphorylation by CK-II; striped triangle, possible site of
phosphorylation by PKC; closed triangle, Tyr residue; open triangle,
residues conserved in putative NLS (30) indicated with
underlines.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Gene expression of each mutant proviral DNA after
transfection of COS cells and viral protein profiles. Pseudotype
viruses were generated by cotransfection of COS cells with
pNL43luc env vector containing either of mutations in IN and an
amphotropic Moloney MuLV envelope expression vector (pJD-1), using
Lipofectamine (GIBCO BRL). Culture supernatants (5 ml) of the
transfected COS cells were harvested at 48 h posttransfection. (A)
p24 levels in culture supernatants were determined by an enzyme
immunoassay system (EIA-II; Abbott Diagnostika). (B) Luciferase
activity in transfected COS cells were measured at 2 days
posttransfection. Cells were washed with PBS and lysed with 1 ml of
cell lysis buffer (Promega). One microliter of each cell lysate was
subjected to the luciferase assay. (C) Virus particles in culture
supernatants (5 ml) of COS cells were precipitated at 48 h
posttransfection by ultracentrifuge (1 h at 315,000 × g using a Beckman TLX-100 centrifuge). Viral proteins were
separated by SDS-12% PAGE. Culture supernatants of mock-transfected
COS cells were precipitated and subjected to SDS-PAGE in parallel as a
negative control. After blotting of proteins to nitrocellulose membrane
(ATTO), the membrane was subjected to a reaction with serum from a
patient and then incubated with horseradish peroxidase-conjugated
anti-human immunoglobulin. Viral proteins were visualized by using the
enhanced chemiluminescence detection system (Amersham). Positions of
the major viral proteins are indicated by their sizes (in kilodaltons)
relative to those of molecular weight (M.W.) markers.
|
|
Proviral formation of HIV-1 IN mutants in dividing cells.
We
previously showed that the single-round infection system with HIV-1
(amphotropic) pseudotypes was useful for estimating the integration
efficiency in vivo by monitoring levels of de novo synthesized viral
DNA and luciferase activity, expressed in infected cells (53,
54). We first assessed whether HIV-1 IN mutants were able to
synthesize viral DNA following infection of susceptible RD cells. At 2 and 6 days postinfection, total DNA was harvested from infected RD
cells, and an aliquot of each DNA sample was subjected to quantitative
PCR analysis (Fig. 3A and
B). We monitored the
formation of various species of viral DNA using primers M667/AA55 for
the early viral DNA species (R/U5) or M667/M661 for the formation of
complete or nearly complete viral DNA (R/gag) (78). An
aliquot of the same DNA sample was also subjected to real-time
quantitative PCR analysis (TaqMan PCR detection; Perkin-Elmer Applied
Biosystems Division) using the R/U5 or R/gag specific internal probe.
Relative to the WT, the T66A, T93A, T125A, Y143G, S195A, K211N G/R, and
S283A mutants showed comparable levels of early (Fig. 3A) and complete
or nearly complete viral DNA (Fig. 3B) at 2 days postinfection. These
results indicated that none of these mutations affected reverse
transcription. The stability of de novo synthesized viral DNA was
monitored by measuring the level at 6 days postinfection. This level
varied among mutants, probably due to their different integration
activities. On the other hand, K186Q and
KRK mutants produced very
low levels of R/gag (~10% of the WT level), indicating severe
impairment of reverse transcription prominently at the late step in
these mutants.


View larger version (3318K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of IN mutants in dividing cells. Each virus was
prepared by cotransfection of COS cells with pNL43luc env vector and
pJD-1. The DNase-treated supernatants containing ~10 ng of p24 were
inoculated into RD cells or PBLs. At 2 or 6 days postinfection, as
indicated on the left, the entire cell culture was harvested. Total DNA
was extracted from infected RD cells and subjected to PCR analysis with
the primer pairs for R/U5 (A) and R/gag (B) and the two-LTR circle (C).
For HIV-1 DNA standards, 50 to 100,000 copies of linearized HIV-1
JR-CSF DNA were amplified in parallel. Amplified products were resolved
on 2% agar gel and visualized by Syber-Green staining (FMC
Bioproduct). Virus treated at 65°C for 30 min prior to inoculation
was used as a heat-inactivated control (HI). After 4 days of infection,
the entire cells were harvested and washed with PBS. The cell pellets
were resuspended with 200 µl (for RD cells) (D) and 100 µl (for
PBLs) (E) of luciferase lysis buffer (Promega Corp.). Ten microliters
of each cell lysate was subjected to luciferase assay as described in
Materials and Methods. Luciferase activities are shown in units per
microliter.
|
|
All mutants showed comparable levels of Luc activity following
transfection of COS cells and produced comparable levels of
viral DNA
after infection, with the exception of the K186Q and

KRK mutants.
Thus, we could estimate the relative integration
efficiency directly by
measuring Luc activity following infection
of RD cells. We repeated
this experiment more than five times
with independently prepared
viruses, and a representative experiment
is shown in Fig.
3D. The level
of Luc activity in T125A was always
high, ranging from 100 to 120% of
the WT level. On the other hand,
T66A, T93A, S195A, S283A, Y143G, and
K211N G/R mutants showed
varied Luc activities of 60 to 80%, 25 to
55%, 60 to 80%, 40 to
80%, 85 to 100%, and 40 to 60% of the WT
level, respectively.
Furthermore, we performed PCR analysis of de novo
synthesized
viral DNA using primer pairs which amplify sequences unique
to
the two-LTR-containing circular DNA. The two-LTR-containing circular
DNA is thought to be produced by host nuclear enzymes as an alternative
to correct integration by IN and is formed in the absence of functional
IN. The PCR amplification of this structure is therefore confirmation
of a specific abrogation of integration. The HIV-1 IN catalytic-site
mutant D116G (
54) was used as a control for the
integration-defective
mutant. We clearly detected an amplified fragment
corresponding
to the two-LTR circle junction in DNA samples from RD
cells infected
with T66A, T93A, K211N G/R, and D116G mutants. However,
it was
only weakly detected in the WT, S195A, and Y143G samples (Fig.
3C). Thus, the lower levels of Luc activity associated with T66A,
T93A,
and K211N G/R most probably represent lowered integration
efficiencies
induced by each mutation. On the other hand, as expected
from the low
level of viral DNA synthesis, K186Q and

KRK did
not exhibit
detectable levels of Luc activity. We also examined
these mutants using
human PBLs as primary dividing target cells
for virus infection (Fig.
3E). In most mutants, the Luc activity
relative to WT levels was
similar to that obtained in RD cells,
although there were slight
differences in the magnitude of the
effect of each mutation between RD
cells and PBLs. However, the
magnitude also varied among PBLs isolated
from different blood
donors (data not shown). For example, the level of
Y143G, which
showed 85 to 100% of WT level in RD cells, was always
reduced
to around 50% of the WT level. Thus, there are slight
differences
in the magnitude of the effect of each mutation on proviral
formation
between in vitro-adapted (RD) and primary (PBL) dividing
cells.
Of note, an almost complete lack of proviral formation by K186Q and

KRK in RD cells was found in primary cells, PBLs and
MDMs (data not
shown). K186 to 188 overlapped with the central
polypurine tract (cPPT)
which is thought to function as a second
priming site for viral
plus-strand DNA (
10). To examine whether
abrogation of viral
DNA synthesis was due to the destruction of
the cPPT function by K186Q
or

KRK mutations, we performed the
trans complementation
test in vivo as described previously (
54).
Briefly, we
prepared pseudotype viruses by cotransfection of COS
cells with the
pJD-1 vector, the pNL43luc

env vector (WT, D116G,
K186Q, or

KRK),
and the pNL43thy

env vector, which is identical
to the pNL43luc

env
vector except that it carries the mouse
thy-1.2 gene instead
of the
luc gene (
62). As shown in Fig.
4, defects
in the
trans-acting
function, such as a catalytic site mutant
of IN, D116G was efficiently
complemented. In contrast, defects
in the
cis-acting
function were not complemented as seen in DEL10
in which both the U3att
and U5att regions were deleted (
53).
Luc activity after
infection of RD cells with K186Q or

KRK was
restored by this
complementation (Fig.
4) to levels as efficient
as those of D116G or
the WT. Thus, viral RNA containing the K186Q
or

KRK mutations could
be efficiently reverse transcribed, integrated,
and efficiently
expressed if WT IN were provided. These results
suggest that low levels
of K186Q and

KRK reverse transcription
might not be simply due to a
perturbation of the structure or
function of the cPPT. Alternatively,
we suggest that the KRK motif
is critical for HIV-1 IN to function as
an antiterminator of the
central plus strand termination, as has been
previously proposed
(
11).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
trans-complementation of K186Q and
KRK. Pseudotype viruses were obtained by cotransfection of COS cells
with pJD-1 and WT or mutant pNL43luc env vector. In rescue
experiments, pseudotype viruses were prepared by cotransfection with
the pJD-1 vector and pairs of each of two different mutant
pNL43luc env vectors, indicated below the columns. For pairs of
mutant and WT vectors, pNL43thy env vector (61), which
contains the WT IN and replaces the mouse thy1.2 gene with
the luc gene, was used. Infection was performed as described
for Fig. 3. A 1-ml aliquot of each virus was inoculated into 5 × 104 RD cells. At 3 days postinfection, the entire culture
was harvested and subjected to the luciferase assay as described in
Fig. 3. Luciferase activity was determined after subtraction of
background level.
|
|
Proviral formation of HIV-1 IN mutants in nondividing cells.
A
feature of HIV-1 distinct among retroviruses is their highly efficient
proviral formation and replication in nondividing cells. To examine the
effects of each HIV-1 IN mutation on this, we examined the efficiency
of proviral formation of HIV-1 IN mutants using human primary MDMs as
nondividing cells for virus infection. To estimate the relative
integration efficiency of each mutant, Luc activity was measured in the
infected MDMs at 4 days postinfection (Fig.
5A). Luc activity of each mutant relative
to that in WT MDMs was similar to that obtained in RD cells or PBLs
(Fig. 3D and E). Of note, relative Luc activity of Y143G mutant in MDMs (20 to 30% of WT level) was significantly lower than that obtained in
RD cells (85 to 100% of WT level). In addition, neither K186Q nor
KRK produced significant levels of Luc activity in MDMs as was
observed in RD cells and PBLs. We reproduced similar results using
independent MDMs isolated from more than 10 different healthy blood
donors. Furthermore, we examined each mutation by pseudotyping with the
HIV-1 macrophage-tropic envelope (pJR-FL). In all but mutant Y143G,
pseudotyping with the pJR-FL envelope (Fig. 5B) did not significantly
alter their relative Luc activities (compare Fig. 5A and B). However,
in the case of Y143G, relative Luc activity was significantly reduced
by pseudotyping with the pJR-FL envelope, most probably due to a
lowered multiplicity of infection (MOI). Thus, we found that the effect
of Y143G was unique in that the magnitude of the effect was
significantly enhanced in nondividing cells but only weakly detected in
dividing cells.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
Viral gene expression after infection of MDMs. Each
virus was prepared by cotransfection to COS cells with pNL43luc env
vector and pJD-1 (A, C, and D) or HIV-1 macrophage-tropic envelope
expression vector (pJR-FL) (B). The supernatants harvested and treated
with DNase at 48 h posttransfection were used to inoculate MDMs
(A, B, and D) or RD cells (C). At 4 days postinfection, the entire
cells were harvested and washed with PBS. Cell pellets were lysed with
150 µl of luciferase lysis buffer (Promega). Ten microliters of each
cell lysate was subjected to the luciferase assay as described in
Materials and Methods.
|
|
Analysis of Y143G mutant with or without additional vpr
mutation.
Transport of the PIC from the cytoplasm into the nucleus
is thought to be a key step in establishing HIV-1 proviral DNA
formation in nondividing cells. Recent evidence suggests that Vpr plays a key regulatory role in this process by binding to karyopherin alpha,
a cellular receptor for NLS, thereby increasing its affinity for NLS
(63, 64). The genetic analysis of HIV-1 IN mutants described
above suggests a partial abrogation of nuclear transport function
associated with the Y143G mutation. Firstly, to analyze Vpr-defective
HIV-1 under our experimental conditions, we generated a Vpr-defective
HIV-1 mutant (
Vpr) by introducing a stop codon (TAA) in the
vpr open reading frame at nt 5624 to 5626 to avoid alteration of the vif gene. Mutants carrying either the
single mutation Y143G or
Vpr produced levels of Luc activity
equivalent to WT levels after infection of RD cells (Fig. 5C). However,
less activity (20 to 30% of WT levels) was observed after infection of
MDMs (Fig. 5D). This result suggests that the effect of Y143G mutation
on proviral DNA formation in MDMs might be equivalent to that of
Vpr
mutation. To confirm this further, we examined levels of de novo
synthesized viral DNA after infection of MDMs with Y143G or
Vpr
(Fig. 6). The level of the early product
(R/U5) produced by Y143G or
Vpr was ~50% of the WT level at 3 days postinfection (Fig. 6A). Both mutants produced significantly lower
levels of the late product (R/gag), less than 30% of the WT level at 3 days postinfection (Fig. 6B), reaching 50 to 80% of the WT level at 4 to 6 days postinfection (data not shown). These results suggest that
Y143G or
Vpr might initiate reverse transcription with almost the
same efficiency as the WT. However the completion of reverse transcription was delayed by Y143G or
Vpr mutations. Finally, we
determined the level of the two-LTR circle form of viral DNA in DNA
samples harvested at 4 days after infection of MDMs. No significant
band corresponding to the amplified two-LTR junction was detected in
any sample, except in the DNA sample infected in parallel with D116G
(Fig. 6C). Since the level of R/gag products produced by Y143G or
Vpr reached around 50 to 80% of the WT level at 4 or 6 days
postinfection (data not shown), the lack of detection of the two-LTR
junction probably mainly reflects retardation in the nuclear transport
of de novo synthesized DNA. Thus, under our experimental conditions,
the effect of the Y143G mutation on formation of proviral DNA was
equivalent to that of
Vpr in dividing and nondividing cells.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Quantitative analysis of de novo synthesized viral DNA
and formation of two-LTR circles after infection of MDMs. Infection of
MDMs with virus was performed as described in Fig. 3. At 3 (A and B)
and 4 (C) days postinfection, as indicated on the left, the entire cell
culture was harvested and PCR analysis was performed as described in
Materials and Methods.
|
|
Finally, to examine the additive effect of Y143G and

Vpr mutations
on proviral DNA formation, we generated a double-mutant
HIV-1, carrying
both mutations (Y143G&

Vpr). As shown in Fig.
5D, Luc activity
produced by Y143G&

Vpr was reduced to less than
10% of the WT level
in MDMs, concomitant with the lower rate of
synthesis of R/gag products
(Fig.
6B). In addition, Y143G&

Vpr
showed a significant reduction in
Luc activity (40% of the WT
level) in RD cells, while the single
mutants, Y143G or

Vpr, produced
levels of Luc activity equivalent to
the WT level (Fig.
5C). Thus,
we demonstrated that the effects of the
Y143G mutation were similar
to

Vpr mutation and had synergistic
effects on proviral formation
at steps prior to integration. These
results indicate that Y143
might be a critical residue for efficient
proviral formation in
nondividing cells, most probably by facilitating
nuclear transport
of the PIC in combination with
Vpr.
Nuclear localization of HIV-1 IN fused to GFP.
To more
directly address the karyophilic properties of HIV-1 IN and the effect
of each mutation on these properties, we generated constructs
expressing full-length HIV-1 IN fused to GFP protein (pGFP-IN). To
examine the subcellular localization of HIV-1 IN, HeLa cells were
transfected with the pGFP-IN vector and subjected to analysis by
confocal microscopy. At 24 h posttransfection, GFP-IN accumulated
almost exclusively in the nucleus (Fig.
7B), while GFP control protein without IN
was uniformly scattered throughout both the cytoplasm and the nucleus
(Fig. 7A). Thus, we confirmed that HIV-1 IN possesses strong
karyophilic properties. Finally, we examined the effect of IN mutations
on the karyophilic properties of HIV-1 IN under our experimental
conditions. We found that all IN mutants tested here (Y143G, K186Q,
KRK, and K211N G/R) were almost exclusively localized to the
nucleus, as seen in the WT (Fig. 7C to F). Thus, none of these
mutations significantly affected the karyophilic properties of HIV-1 IN
under this experimental condition. An earlier result suggests that the
NLS of HIV-1 IN is bipartite and consists of the KRK and residues 212 to 219 (31). However, we found that the IN, which lacks the
C-terminal region, residues 181 to 288, retained the karyophilic
properties (data not shown). Thus, lack of defect in the karyophilic
property of HIV-1 IN by a single mutation at KRK or the K212N mutation
might not reflect the bipartite function of the NLS. These results
indicate that perhaps none of these amino acids is directly involved in the NLS function of HIV-1 IN. Together with our genetic analysis, this
leads us to suggest that Y143 is involved in the regulation of
karyophilic properties or the putative NLS in the PIC, effects of which
apparently only occur in the context of the natural course of viral
infection.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 7.
Confocal microscopic analysis of GFP-IN fusion proteins.
HeLa cells were transfected with plasmid expressing GFP only (A), GFP
fused to full-length WT HIV-1 IN (B), or GFP fused to the IN carrying
the mutation Y143G (C), K186Q (D), KRK (E), or K211N G/R (F) by
using Effectene Transfection Reagent (Qiagen). At 24 h
posttransfection, cells were fixed and examined with a confocal
fluorescent microscope.
|
|
 |
DISCUSSION |
Genetic analyses of HIV-1 IN (9, 24, 49, 54, 59, 69,
77) suggest putative roles for IN at steps prior to integration, such as uncoating and reverse transcription. In addition, recent evidence indicating the karyophilic properties of HIV-1 IN suggests important roles of IN for nuclear transport of the PIC. In this study,
to identify critical amino acids in HIV-1 IN required for putative
functions at steps distinct from integration, we generated HIV-1
mutants carrying point or deletion mutations at conserved Ser, Thr,
Tyr, Lys, or Arg residues in HIV-1 IN. None of these mutants affected
levels of proviral gene expression, virus release, or viral protein
processing in the virion particle (Fig. 2), indicating no apparent
effect of these mutations in the late stages of the viral life cycle.
The phenotype of each mutant was evaluated using the human RD cell line
or PBLs as target cells for in vitro-adapted and primary dividing
cells, respectively. Since nuclear transport of HIV-1 PIC is a key step
in establishing proviral DNA formation in nondividing cells such as
macrophages, we also tested each mutant using human MDMs as primary
nondividing cells. Phenotypes of mutants are divided into three groups
according to the steps affected by each mutation: integration, reverse
transcription, and nuclear transport of the PIC.
Residues affecting integration.
Motif analyses of HIV-1 IN
revealed the existence of several possible phosphorylation sites on the
conserved Ser or Thr residues, T66, T93, S195, and S283 for
phosphorylation by CK-II and T125 for phosphorylation by PKC. Although
it has been reported that avian retroviral IN can undergo
phosphorylation at the Ser residue in the carboxyl terminus
(37), phosphorylation of HIV-1 IN in the virus particle has
not been reported. In addition, the phosphorylation status of IN after
infection and its role(s) during the early events of retroviral
infection cycle are poorly understood. Our genetic analyses showed that
each of these mutations might affect the integration step to different
degrees; T66A, T93A, T125A, S195A, and S283A mutants in RD cells varied
from 60 to 80%, 25 to 55%, 100 to 120%, 60 to 80%, or 40 to 80% of
the WT level, respectively. Some of the mutants have been examined
previously using in vitro cell assays or in the context of virus
replication. T66A has been shown to be defective in 3' processing in
vitro (22% of WT activity) and exhibits partially defective
integration (42% of WT activity) (23). However, it has been
reported that T66A replicates with kinetics similar to those of the WT
(9). Consistent with our results, T125A has also been
reported to replicate with kinetics similar to those of the WT
(69). It has been reported that the K211 residue is involved
in the putative NLS function of the IN (31). However, we
could not detect any apparent defect in the karyophilic properties of
HIV-1 IN in our experimental system (Fig. 7). K211N G/R showed a slight
reduction of integration activity to 40 to 60% in dividing and
nondividing cells. Our results are consistent with a previous report
showing that K211N reduced integration activity to 32% of the WT level
(77). Among the mutants, T93A showed the most prominent
effect on integration activity (25 to 55% of the WT level). The loss
of integration activity upon mutation of the T66, T93, T125, S195,
S283, and K211 residues suggests that they form part of the active
site. However, the magnitude of the effect of these mutations was not as dramatic as that of the catalytic site mutation, D116G, which showed
less than 0.5% of the WT activity (54). In conclusion, phosphorylation at these sites, if it occurs, might have little effect
on reverse transcription and nuclear transport of PIC and a slight but
not essential role in integration.
Residues affecting reverse transcription.
The KRK motif,
spanning residues 186 to 188 of HIV-1 IN, has been shown to be critical
for interaction with cellular importin alpha, suggesting its putative
role as the NLS of the PIC (31). However, we could not
detect any apparent effects of K186Q or
KRK on the karyophilic
properties of HIV-1 IN in our experimental system, using the GFP fusion
protein expression system (Fig. 7). Instead, we found an almost
complete lack of viral gene expression due to failure to complete viral
DNA synthesis in RD cells, PBLs, and MDMs. We have previously reported
that mutations within the HHCC motif of IN abolished viral gene
expression completely, due to severe defects at or prior to the
initiation of reverse transcription (54). Since the HHCC
mutants showed WT levels of endogenous RT activity (54) and
binding and entry to target cells were not affected (59), we
hypothesized that the defects caused by the HHCC mutation occur at the
uncoating step. Interestingly, defects in reverse transcription
associated with K186Q and
KRK were found mainly at a late stage,
most probably during plus strand synthesis (Fig. 3). Thus, the effects
of K186Q and
KRK mutations on reverse transcription are different
from those associated with HHCC mutations. The KRK motif overlaps with
the cPPT which is thought to function as a second priming site for
viral plus-strand DNA synthesis (10). However,
trans-complementation of the KRK mutations by WT IN suggests
that this defect is not simply due to a perturbation of the structure
or function of the cPPT. Alternatively, we favor the idea that the KRK
residues might represent a motif critical for the function of HIV-1 IN
as an antiterminator of the central plus strand termination as has been
previously proposed (11). Interestingly, a similar
termination of plus strand synthesis proximal to the cPPT has recently
been reported in the equine infectious anemia virus, suggesting this is
a common feature among lentiviruses (68). Thus, it would be
interesting to examine the exact mechanisms underlying the roles of IN
in the complex mode of HIV-1 reverse transcription and their biological significance.
Residues affecting nuclear transport of PIC.
A feature of
HIV-1 distinctive among retroviruses is their highly efficient proviral
formation and replication in nondividing cells, such as macrophages.
Nuclear transport of HIV-1 PIC is a key step in establishing proviral
DNA formation in nondividing cells. One major object of the present
study was to identify the critical residues of HIV-1 IN involved in its
nuclear transport function. Since the nuclear import function is not
strictly required for infection of dividing cells, we made the
assumption that effects on proviral formation might be evident in MDMs
but slight in RD cells or activated PBLs. Among the mutants tested
here, we found that Y143G showed a significant reduction in viral gene
expression (20 to 30% of the WT level) in MDMs while retaining high
gene expression levels (80 to 100% of the WT level) in RD cells. Our results are in part consistent with previous reports in which point
mutations at Y143 resulted in competent replication with slightly
delayed kinetics in T-cell lines (67, 77). Y143 is well
conserved among mammalian retroviral INs, although nonconservative amino acid substitutions occur naturally at an analogous position in
some INs (23, 39, 44). A nonconservative amino acid
substitution at this position in HIV-2 IN (Y143L) had no effect on
oligonucleotide cleavage, strand joining, or disintegration reaction
(72). Recently, involvement of the Y143 residue of HIV-1 IN
in specific interactions with the att sequences has been
reported using an in vitro photo-cross-linking assay (25).
Of note, the effect of the Y143G mutation on proviral formation was
evident in MDMs but slight in RD cells. We also demonstrated that this
phenotype was quite similar to
Vpr. Vpr is thought to be one of the
key regulatory viral proteins possessing a nuclear transport function
(1, 2, 15, 28, 30, 35, 52, 64). Thus, we suggest that the
Y143G mutation might affect the nuclear transport function of the PIC,
but not integration. Interestingly, in RD cells, one of these (Vpr and
IN) functions might be sufficient for efficient proviral formation.
However, both functions might be necessary, especially in MDMs and to a lesser degree in primary isolated PBLs. In the GFP-IN expression system, we did not see any effect of the Y143G mutation on the karyophilic properties of HIV-1 IN. It is still possible that the
functional role of the Y143 residue involves regulation of the
karyophilic properties or putative NLS in the PIC, the effect of which
is apparent only in the context of the natural course of viral
infection. Alternatively, it is possible that the effect is evident in
nondividing cells. Due to poor transfection efficiency of the GFP-IN
vector into MDMs, we are currently addressing this point using the
lentivirus vector expression system. In addition, the exact region of
the putative NLS in HIV-1 IN remains to be determined, since none of
the mutations tested here showed any apparent effects on the
karyophilic properties of HIV-1 IN in our experimental system. On the
other hand, the lowered rate of completion of reverse transcription in
these mutants suggests that reverse transcription of HIV-1 might be
complete after nuclear entry. A similar correlation between nuclear
entry and completion of reverse transcription has been reported in an
avian retrovirus (50) and HIV-1 (55). Thus, it
would be of interest to identify the nuclear cofactor(s) required for
completion of HIV-1 reverse transcription.
In summary, the present study has identified residues that may be
critical for the putative functional roles(s) of HIV-1 IN
in the steps
prior to integration in dividing and/or nondividing
cells. Nondividing
cells of the monocyte/macrophage lineage are
regarded as the first
target of HIV-1 infection and act as one
of the reservoirs of HIV-1 in
persistent infection in vivo (
16,
17,
33,
45,
60,
65,
71,
76,
80). Thus, identification
of the critical motif in HIV-1 IN or
other components in the PIC
might be important in revealing new aspects
of the HIV-1 life
cycle. Hopefully, it may also contribute to the
development of
new strategies for AIDS treatment and anti-HIV-1
drugs.
 |
ACKNOWLEDGMENTS |
We thank K. Umesono and H. Ogawa for providing the pCMX-SAH/Y145F
vector; D. P. Grandgenett for supplying antiserum against HIV-1 IN
and for good discussions; C. Depienne and K. Morizono for their helpful
technical advice; and Y. Koyanagi for providing pJR-FL and serum from
AIDS patients.
This work was supported by grants from the Ministry of Education,
Science, Sports, and Culture; a grant-in-aid for Scientific Research on
Priority Areas from the Ministry of Culture; the Japan Health Sciences
Foundation; and the Ministry of Science and Technology Agency of Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Immunotherapeutics, Medical Research Division, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Phone: 81 (3) 5803-5799. Fax: 81 (3) 5803-0235. E-mail:
tmasu.impt{at}med.tmd.ac.jp.
 |
REFERENCES |
| 1.
|
Balliet, J. W.,
D. L. Kolson,
G. Eiger,
F. M. Kim,
K. A. McGann,
A. Srinivasan, and R. Collman.
1994.
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.
Virology
200:623-631[CrossRef][Medline].
|
| 2.
|
Bukrinskaya, A. G.,
A. Ghorpade,
N. K. Heinzinger,
T. E. Smithgall,
R. E. Lewis, and M. Stevenson.
1996.
Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA.
Proc. Natl. Acad. Sci. USA
93:367-371[Abstract/Free Full Text].
|
| 3.
|
Bukrinsky, M. I., and O. K. Haffar.
1997.
HIV-1 nuclear import: in search of a leader.
Front. Biosci.
2:578-587.
|
| 4.
|
Bukrinsky, M. I.,
N. Sharova,
T. L. McDonald,
T. Pushkarskaya,
W. G. Tarpley, and M. Stevenson.
1993.
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.
Proc. Natl. Acad. Sci. USA
90:6125-6129[Abstract/Free Full Text].
|
| 5.
|
Burke, C. J.,
G. Sanyal,
M. W. Bruner,
J. A. Ryan,
R. L. LaFemina,
H. L. Robbins,
A. S. Zeft,
C. R. Middaugh, and M. G. Cordingley.
1992.
Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase.
J. Biol. Chem.
267:9639-9644[Abstract/Free Full Text].
|
| 6.
|
Bushman, F. D., and R. Craigie.
1990.
Sequence requirements for integration of Moloney murine leukemia virus DNA in vitro.
J. Virol.
64:5645-5648[Abstract/Free Full Text].
|
| 7.
|
Bushman, F. D.,
A. Engelman,
I. Palmer,
P. Wingfield, and R. Craigie.
1993.
Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding.
Proc. Natl. Acad. Sci. USA
90:3428-3432[Abstract/Free Full Text].
|
| 8.
|
Cai, M.,
R. Zheng,
M. Caffrey,
R. Craigie,
G. M. Clore, and A. M. Gronenborn.
1997.
Solution structure of the N-terminal zinc binding domain of HIV-1 integrase.
Nat. Struct. Biol.
4:567-577[CrossRef][Medline].
|
| 9.
|
Cannon, P. M.,
W. Wilson,
E. Byles,
S. M. Kingsman, and A. J. Kingsman.
1994.
Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues.
J. Virol.
68:4768-4775[Abstract/Free Full Text].
|
| 10.
|
Charneau, P., and F. Clavel.
1991.
A single-stranded gap in human immunodeficiency virus unintegrated linear DNA defined by a central copy of the polypurine tract.
J. Virol.
65:2415-2421[Abstract/Free Full Text].
|
| 11.
|
Charneau, P.,
G. Mirambeau,
P. Roux,
S. Paulous,
H. Buc, and F. Clavel.
1994.
HIV-1 reverse transcription. A termination step at the center of the genome.
J. Mol. Biol.
241:651-662[CrossRef][Medline].
|
| 12.
|
Chen, H., and A. Engelman.
1998.
The barrier-to-autointegration protein is a host factor for HIV type 1 integration.
Proc. Natl. Acad. Sci. USA
95:15270-15274[Abstract/Free Full Text].
|
| 13.
|
Chow, S. A., and P. O. Brown.
1994.
Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates.
J. Virol.
68:3896-3907[Abstract/Free Full Text].
|
| 14.
|
Chow, S. A.,
K. A. Vincent,
V. Ellison, and P. O. Brown.
1992.
Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus.
Science
255:723-726[Abstract/Free Full Text].
|
| 15.
|
Connor, R. I.,
B. K. Chen,
S. Choe, and N. R. Landau.
1995.
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
Virology
206:935-944[CrossRef][Medline].
|
| 16.
|
Connor, R. I., and D. D. Ho.
1994.
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.
J. Virol.
68:4400-4408[Abstract/Free Full Text].
|
| 17.
|
Cornelissen, M.,
G. Mulder-Kampinga,
J. Veenstra,
F. Zorgdrager,
C. Kuiken,
S. Hartman,
J. Dekker,
L. van der Hoek,
C. Sol,
R. Coutinho, et al.
1995.
Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.
J. Virol.
69:1810-1818[Abstract].
|
| 18.
|
Daniel, R.,
R. A. Katz, and A. M. Skalka.
1999.
A role for DNA-PK in retroviral DNA integration.
Science
284:644-647[Abstract/Free Full Text].
|
| 19.
|
Dyda, F.,
A. B. Hickman,
T. M. Jenkins,
A. Engelman,
R. Craigie, and D. R. Davies.
1994.
Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases.
Science
266:1981-1986[Abstract/Free Full Text].
|
| 20.
|
Eijkelenboom, A. P.,
R. A. Lutzke,
R. Boelens,
R. H. Plasterk,
R. Kaptein, and K. Hard.
1995.
The DNA-binding domain of HIV-1 integrase has an SH3-like fold.
Nat. Struct. Biol.
2:807-810[CrossRef][Medline].
|
| 21.
|
Ellison, V.,
J. Gerton,
K. A. Vincent, and P. O. Brown.
1995.
An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer.
J. Biol. Chem.
270:3320-3326[Abstract/Free Full Text].
|
| 22.
|
Engelman, A.,
F. D. Bushman, and R. Craigie.
1993.
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex.
EMBO J.
12:3269-3275[Medline].
|
| 23.
|
Engelman, A., and R. Craigie.
1992.
Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.
J. Virol.
66:6361-6369[Abstract/Free Full Text].
|
| 24.
|
Engelman, A.,
G. Englund,
J. M. Orenstein,
M. A. Martin, and R. Craigie.
1995.
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.
J. Virol.
69:2729-2736[Abstract].
|
| 25.
|
Esposito, D., and R. Craigie.
1998.
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction.
EMBO J.
17:5832-5843[CrossRef][Medline].
|
| 26.
|
Farnet, C. M., and F. D. Bushman.
1997.
HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro.
Cell
88:483-492[CrossRef][Medline].
|
| 27.
|
Farnet, C. M.,
B. Wang,
J. R. Lipford, and F. D. Bushman.
1996.
Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.
Proc. Natl. Acad. Sci. USA
93:9742-9747[Abstract/Free Full Text].
|
| 28.
|
Fletcher, T. M. R.,
B. Brichacek,
N. Sharova,
M. A. Newman,
G. Stivahtis,
P. M. Sharp,
M. Emerman,
B. H. Hahn, and M. Stevenson.
1996.
Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).
EMBO J.
15:6155-6165[Medline].
|
| 29.
|
Fouchier, R. A.,
B. E. Meyer,
J. H. Simon,
U. Fischer, and M. H. Malim.
1997.
HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.
EMBO J.
16:4531-4539[CrossRef][Medline].
|
| 30.
|
Freed, E. O.,
G. Englund,
F. Maldarelli, and M. A. Martin.
1997.
Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection.
Cell
88:171-174[CrossRef][Medline].
|
| 31.
|
Gallay, P.,
T. Hope,
D. Chin, and D. Trono.
1997.
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway.
Proc. Natl. Acad. Sci. USA
94:9825-9830[Abstract/Free Full Text].
|
| 32.
|
Gallay, P.,
S. Swingler,
J. Song,
F. Bushman, and D. Trono.
1995.
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.
Cell
83:569-576[CrossRef][Medline].
|
| 33.
|
Gartner, S.,
P. Markovits,
D. M. Markovitz,
M. H. Kaplan,
R. C. Gallo, and M. Popovic.
1986.
The role of mononuclear phagocytes in HTLV-III/LAV infection.
Science
233:215-219[Abstract/Free Full Text].
|
| 34.
|
Goff, S. P.
1992.
Genetics of retroviral integration.
Annu. Rev. Genet.
26:527-544[CrossRef][Medline].
|
| 35.
|
Heinzinger, N. K.,
M. I. Bukinsky,
S. A. Haggerty,
A. M. Ragland,
V. Kewalramani,
M. A. Lee,
H. E. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1994.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315[Abstract/Free Full Text].
|
| 36.
|
Hindmarsh, P.,
T. Ridky,
R. Reeves,
M. Andrake,
A. M. Skalka, and J. Leis.
1999.
HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro.
J. Virol.
73:2994-3003[Abstract/Free Full Text].
|
| 37.
|
Horton, R.,
S. Mumm, and D. P. Grandgenett.
1988.
Avian retrovirus pp32 DNA endonuclease is phosphorylated on Ser in the carboxyl-terminal region.
J. Virol.
62:2067-2075[Abstract/Free Full Text].
|
| 38.
|
Jacque, J. M.,
A. Mann,
H. Enslen,
N. Sharova,
B. Brichacek,
R. J. Davis, and M. Stevenson.
1998.
Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase.
EMBO J.
17:2607-2618[CrossRef][Medline].
|
| 39.
|
Johnson, M. S.,
M. A. McClure,
D. F. Feng,
J. Gray, and R. F. Doolittle.
1986.
Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes.
Proc. Natl. Acad. Sci. USA
83:7648-7652[Abstract/Free Full Text].
|
| 40.
|
Kalpana, G. V.,
S. Marmon,
W. Wang,
G. R. Crabtree, and S. P. Goff.
1994.
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5.
Science
266:2002-2006[Abstract/Free Full Text].
|
| 41.
|
Kalpana, G. V.,
A. Reicin,
G. S. Cheng,
M. Sorin,
S. Paik, and S. P. Goff.
1999.
Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase.
Virology
259:274-285[CrossRef][Medline].
|
| 42.
|
Katz, R. A., and A. M. Skalka.
1994.
The retroviral enzymes.
Annu. Rev. Biochem.
63:133-173[CrossRef][Medline].
|
| 43.
|
Katzman, M., and M. Sudol.
1996.
Influence of subterminal viral DNA nucleotides on differential susceptibility to cleavage by human immunodeficiency virus type 1 and visna virus integrases.
J. Virol.
70:9069-9073[Abstract].
|
| 44.
|
Khan, E.,
J. P. Mack,
R. A. Katz,
J. Kulkosky, and A. M. Skalka.
1991.
Retroviral integrase domains: DNA binding and the recognition of LTR sequences.
Nucleic Acids Res.
19:851-860[Abstract/Free Full Text].
|
| 45.
|
Koenig, S.,
H. E. Gendelman,
J. M. Orenstein,
M. C. Dal Canto,
G. H. Pezeshkpour,
M. Yungbluth,
F. Janotta,
A. Aksamit,
M. A. Martin, and A. S. Fauci.
1986.
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.
Science
233:1089-1093[Abstract/Free Full Text].
|
| 46.
|
Kulkosky, J.,
K. S. Jones,
R. A. Katz,
J. P. Mack, and A. M. Skalka.
1992.
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases.
Mol. Cell. Biol.
12:2331-2338[Abstract/Free Full Text].
|
| 47.
|
LaFemina, R. L.,
P. L. Callahan, and M. G. Cordingley.
1991.
Substrate specificity of recombinant human immunodeficiency virus integrase protein.
J. Virol.
65:5624-5630[Abstract/Free Full Text].
|
| 48.
|
LaFemina, R. L.,
C. L. Schneider,
H. L. Robbins,
P. L. Callahan,
K. LeGrow,
E. Roth,
W. A. Schleif, and E. A. Emini.
1992.
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells.
J. Virol.
66:7414-7419[Abstract/Free Full Text].
|
| 49.
|
Leavitt, A. D.,
G. Robles,
N. Alesandro, and H. E. Varmus.
1996.
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection.
J. Virol.
70:721-728[Abstract].
|
| 50.
|
Lee, Y. M., and J. M. Coffin.
1991.
Relationship of avian retrovirus DNA synthesis to integration in vitro.
Mol. Cell. Biol.
11:1419-1430[Abstract/Free Full Text].
|
| 51.
|
Lodi, P. J.,
J. A. Ernst,
J. Kuszewski,
A. B. Hickman,
A. Engelman,
R. Craigie,
G. M. Clore, and A. M. Gronenborn.
1995.
Solution structure of the DNA binding domain of HIV-1 integrase.
Biochemistry
34:9826-9833[CrossRef][Medline].
|
| 52.
|
Lu, Y. L.,
P. Spearman, and L. Ratner.
1993.
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.
J. Virol.
67:6542-6550[Abstract/Free Full Text].
|
| 53.
|
Masuda, T.,
M. J. Kuroda, and S. Harada.
1998.
Specific and independent recognition of U3 and U5 att sites by human immunodeficiency virus type 1 integrase in vivo.
J. Virol.
72:8396-8402[Abstract/Free Full Text].
|
| 54.
|
Masuda, T.,
V. Planelles,
P. Krogstad, and I. S. Chen.
1995.
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain.
J. Virol.
69:6687-6696[Abstract].
|
| 55.
|
Miller, M. D.,
B. Wang, and F. D. Bushman.
1995.
Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro.
J. Virol.
69:3938-3944[Abstract].
|
| 56.
|
Murphy, J. E., and S. P. Goff.
1989.
Construction and analysis of deletion mutations in the U5 region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription.
J. Virol.
63:319-327[Abstract/Free Full Text].
|
| 57.
|
Murphy, J. E., and S. P. Goff.
1992.
A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage of both ends by the viral integrase in vivo.
J. Virol.
66:5092-5095[Abstract/Free Full Text].
|
| 58.
|
Nadler, S. G.,
D. Tritschler,
O. Haffar,
J. Blake,
A. G. Bruce, and J. S. Cleaveland.
1997.
Differential expression and sequence-specific interaction of karyopherin alpha with nuclear localization sequences.
J. Biol. Chem.
272:4310-4315[Abstract/Free Full Text].
|
| 59.
|
Nakamura, T.,
T. Masuda,
T. Goto,
K. Sano,
M. Nakai, and S. Harada.
1997.
Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation.
Biochem. Biophys. Res. Commun.
239:715-722[CrossRef][Medline].
|
| 60.
|
O'Brien, W. A., and R. J. Pomerantz.
1996.
HIV infection and associated diseases, p. 815-836.
In
N. Nathanson, R. Ahmed, F. Gonzalez-Scarano, D. E. Griffin, K. V. Holmes, F. A. Murphy, H. Robinson, and L. Lippincott-Raven (ed.), Viral pathogenesis. Lippincott-Raven, Philadelphia, Pa.
|
| 61.
|
Panganiban, A. T., and H. M. Temin.
1983.
The terminal nucleotides of retrovirus DNA are required for integration but not virus production.
Nature
306:155-160[CrossRef][Medline].
|
| 62.
|
Planelles, V.,
A. Haislip,
E. S. Withers-Ward,
S. A. Stewart,
Y. Xie,
N. P. Shah, and I. S. Chen.
1995.
A new reporter system for detection of retroviral infection.
Gene Ther.
2:369-376[Medline].
|
| 63.
|
Popov, S.,
M. Rexach,
L. Ratner,
G. Blobel, and M. Bukrinsky.
1998.
Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex.
J. Biol. Chem.
273:13347-13352[Abstract/Free Full Text].
|
| 64.
|
Popov, S.,
M. Rexach,
G. Zybarth,
N. Reiling,
M. A. Lee,
L. Ratner,
C. M. Lane,
M. S. Moore,
G. Blobel, and M. Bukrinsky.
1998.
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex.
EMBO J.
17:909-917[CrossRef][Medline].
|
| 65.
|
Schuitemaker, H.,
M. Koot,
N. A. Kootstra,
M. W. Dercksen,
R. E. de Goede,
R. P. van Steenwijk,
J. M. Lange,
J. K. Schattenkerk,
F. Miedema, and M. Tersmette.
1992.
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
J. Virol.
66:1354-1360[Abstract/Free Full Text].
|
| 66.
|
Sherman, P. A., and J. A. Fyfe.
1990.
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.
Proc. Natl. Acad. Sci. USA
87:5119-5123[Abstract/Free Full Text].
|
| 67.
|
Shin, C. G.,
B. Taddeo,
W. A. Haseltine, and C. M. Farnet.
1994.
Genetic analysis of the human immunodeficiency virus type 1 integrase protein.
J. Virol.
68:1633-1642[Abstract/Free Full Text].
|
| 68.
|
Stetor, S. R.,
J. W. Rausch,
M. J. Guo,
J. P. Burnham,
L. R. Boone,
M. J. Waring, and S. F. Le Grice.
1999.
Characterization of (+) strand initiation and termination sequences located at the center of the equine infectious anemia virus genome.
Biochemistry
38:3656-3667[CrossRef][Medline].
|
| 69.
|
Taddeo, B.,
F. Carlini,
P. Verani, and A. Engelman.
1996.
Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity.
J. Virol.
70:8277-8284[Abstract].
|
| 70.
|
van Gent, D. C.,
C. Vink,
A. A. Groeneger, and R. H. Plasterk.
1993.
Complementation between HIV integrase proteins mutated in different domains.
EMBO J.
12:3261-3267[Medline].
|
| 71.
|
van't Wout, A. B.,
N. A. Koostra,
G. A. Mulder-Kampinga,
N. Albrecht-van Lent,
H. J. Scherpbier,
J. Veenstra,
K. Boer,
R. A. Coutinho,
F. Miedema, and H. Schuitemaker.
1994.
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.
J. Clin. Invest.
94:2060-2067.
|
| 72.
|
Varmus, H. E., and P. O. Brown.
1989.
Retroviruses, p. 53-108.
In
M. Howe, and D. Berg (ed.), Mobile DNA. American Society for Microbiology, Washington, D.C.
|
| 73.
|
Vincent, K. A.,
V. Ellison,
S. A. Chow, and P. O. Brown.
1993.
Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations.
J. Virol.
67:425-437[Abstract/Free Full Text].
|
| 74.
|
Vink, C.,
D. C. van Gent,
Y. Elgersma, and R. H. Plasterk.
1991.
Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage.
J. Virol.
65:4636-4644[Abstract/Free Full Text].
|
| 75.
|
Whitcomb, J. M., and S. H. Hughes.
1992.
Retroviral reverse transcription and integration: progress and problems.
Annu. Rev. Cell Biol.
8:275-306[CrossRef].
|
| 76.
|
Wiley, C. A.,
R. D. Schrier,
J. A. Nelson,
P. W. Lampert, and M. B. Oldstone.
1986.
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.
Proc. Natl. Acad. Sci. USA
83:7089-7093[Abstract/Free Full Text].
|
| 77.
|
Wiskerchen, M., and M. A. Muesing.
1995.
Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.
J. Virol.
69:376-386[Abstract].
|
| 78.
|
Zack, J. A.,
S. J. Arrigo,
S. R. Weitsman,
A. S. Go,
A. Haislip, and I. S. Chen.
1990.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Cell
61:213-222[CrossRef][Medline].
|
| 79.
|
Zheng, R.,
T. M. Jenkins, and R. Craigie.
1996.
Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity.
Proc. Natl. Acad. Sci. USA
93:13659-13664[Abstract/Free Full Text].
|
| 80.
|
Zhu, K.,
M. L. Cordeiro,
J. Atienza,
W. E. Robinson, Jr., and S. A. Chow.
1999.
Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids.
J. Virol.
73:3309-3316[Abstract/Free Full Text].
|
Journal of Virology, May 2000, p. 4795-4806, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Woodward, C. L., Prakobwanakit, S., Mosessian, S., Chow, S. A.
(2009). Integrase Interacts with Nucleoporin NUP153 To Mediate the Nuclear Import of Human Immunodeficiency Virus Type 1. J. Virol.
83: 6522-6533
[Abstract]
[Full Text]
-
Wilkinson, T. A., Januszyk, K., Phillips, M. L., Tekeste, S. S., Zhang, M., Miller, J. T., Le Grice, S. F. J., Clubb, R. T., Chow, S. A.
(2009). Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase. J. Biol. Chem.
284: 7931-7939
[Abstract]
[Full Text]
-
McKee, C. J., Kessl, J. J., Shkriabai, N., Dar, M. J., Engelman, A., Kvaratskhelia, M.
(2008). Dynamic Modulation of HIV-1 Integrase Structure and Function by Cellular Lens Epithelium-derived Growth Factor (LEDGF) Protein. J. Biol. Chem.
283: 31802-31812
[Abstract]
[Full Text]
-
Dobard, C. W., Briones, M. S., Chow, S. A.
(2007). Molecular Mechanisms by Which Human Immunodeficiency Virus Type 1 Integrase Stimulates the Early Steps of Reverse Transcription. J. Virol.
81: 10037-10046
[Abstract]
[Full Text]
-
Wen, X., Duus, K. M., Friedrich, T. D., de Noronha, C. M. C.
(2007). The HIV1 Protein Vpr Acts to Promote G2 Cell Cycle Arrest by Engaging a DDB1 and Cullin4A-containing Ubiquitin Ligase Complex Using VprBP/DCAF1 as an Adaptor. J. Biol. Chem.
282: 27046-27057
[Abstract]
[Full Text]
-
Mousnier, A., Kubat, N., Massias-Simon, A., Segeral, E., Rain, J.-C., Benarous, R., Emiliani, S., Dargemont, C.
(2007). von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc. Natl. Acad. Sci. USA
104: 13615-13620
[Abstract]
[Full Text]
-
Tsurutani, N., Yasuda, J., Yamamoto, N., Choi, B.-I., Kadoki, M., Iwakura, Y.
(2007). Nuclear Import of the Preintegration Complex Is Blocked upon Infection by Human Immunodeficiency Virus Type 1 in Mouse Cells. J. Virol.
81: 677-688
[Abstract]
[Full Text]
-
Nishitsuji, H., Kohara, M., Kannagi, M., Masuda, T.
(2006). Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration.. J. Virol.
80: 7658-7666
[Abstract]
[Full Text]
-
Hamamoto, S., Nishitsuji, H., Amagasa, T., Kannagi, M., Masuda, T.
(2006). Identification of a Novel Human Immunodeficiency Virus Type 1 Integrase Interactor, Gemin2, That Facilitates Efficient Viral cDNA Synthesis In Vivo.. J. Virol.
80: 5670-5677
[Abstract]
[Full Text]
-
Nomura, Y., Masuda, T., Kawai, G.
(2006). Structural Analysis of a Mutant of the HIV-1 Integrase Zinc Finger Domain That Forms a Single Conformation.. J Biochem
139: 753-759
[Abstract]
[Full Text]
-
Tardif, M. R., Tremblay, M. J.
(2005). LFA-1 Is a Key Determinant for Preferential Infection of Memory CD4+ T Cells by Human Immunodeficiency Virus Type 1. J. Virol.
79: 13714-13724
[Abstract]
[Full Text]
-
Jin, S., Chen, C., Montelaro, R. C.
(2005). Equine Infectious Anemia Virus Gag p9 Function in Early Steps of Virus Infection and Provirus Production. J. Virol.
79: 8793-8801
[Abstract]
[Full Text]
-
Wilhelm, M., Wilhelm, F.-X.
(2005). Role of Integrase in Reverse Transcription of the Saccharomyces cerevisiae Retrotransposon Ty1. Eukaryot Cell
4: 1057-1065
[Abstract]
[Full Text]
-
Lu, R., Limon, A., Ghory, H. Z., Engelman, A.
(2005). Genetic Analyses of DNA-Binding Mutants in the Catalytic Core Domain of Human Immunodeficiency Virus Type 1 Integrase. J. Virol.
79: 2493-2505
[Abstract]
[Full Text]
-
Lu, R., Limon, A., Devroe, E., Silver, P. A., Cherepanov, P., Engelman, A.
(2004). Class II Integrase Mutants with Changes in Putative Nuclear Localization Signals Are Primarily Blocked at a Postnuclear Entry Step of Human Immunodeficiency Virus Type 1 Replication. J. Virol.
78: 12735-12746
[Abstract]
[Full Text]
-
Ikeda, T., Nishitsuji, H., Zhou, X., Nara, N., Ohashi, T., Kannagi, M., Masuda, T.
(2004). Evaluation of the Functional Involvement of Human Immunodeficiency Virus Type 1 Integrase in Nuclear Import of Viral cDNA during Acute Infection. J. Virol.
78: 11563-11573
[Abstract]
[Full Text]
-
Llano, M., Vanegas, M., Fregoso, O., Saenz, D., Chung, S., Peretz, M., Poeschla, E. M.
(2004). LEDGF/p75 Determines Cellular Trafficking of Diverse Lentiviral but Not Murine Oncoretroviral Integrase Proteins and Is a Component of Functional Lentiviral Preintegration Complexes. J. Virol.
78: 9524-9537
[Abstract]
[Full Text]
-
Maertens, G., Cherepanov, P., Debyser, Z., Engelborghs, Y., Engelman, A.
(2004). Identification and Characterization of a Functional Nuclear Localization Signal in the HIV-1 Integrase Interactor LEDGF/p75. J. Biol. Chem.
279: 33421-33429
[Abstract]
[Full Text]
-
Parveen, Z., Mukhtar, M., Goodrich, A., Acheampong, E., Dornburg, R., Pomerantz, R. J.
(2004). Cross-Packaging of Human Immunodeficiency Virus Type 1 Vector RNA by Spleen Necrosis Virus Proteins: Construction of a New Generation of Spleen Necrosis Virus-Derived Retroviral Vectors. J. Virol.
78: 6480-6488
[Abstract]
[Full Text]
-
Bonnenfant, S., Thomas, C. M., Vita, C., Subra, F., Deprez, E., Zouhiri, F., Desmaele, D., d'Angelo, J., Mouscadet, J. F., Leh, H.
(2004). Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents. J. Virol.
78: 5728-5736
[Abstract]
[Full Text]
-
Zhu, K., Dobard, C., Chow, S. A.
(2004). Requirement for Integrase during Reverse Transcription of Human Immunodeficiency Virus Type 1 and the Effect of Cysteine Mutations of Integrase on Its Interactions with Reverse Transcriptase. J. Virol.
78: 5045-5055
[Abstract]
[Full Text]
-
Deprez, E., Barbe, S., Kolaski, M., Leh, H., Zouhiri, F., Auclair, C., Brochon, J.-C., Le Bret, M., Mouscadet, J.-F.
(2004). Mechanism of HIV-1 Integrase Inhibition by Styrylquinoline Derivatives in Vitro. Mol. Pharmacol.
65: 85-98
[Abstract]
[Full Text]
-
Devroe, E., Engelman, A., Silver, P. A.
(2003). Intracellular transport of human immunodeficiency virus type 1 integrase. J. Cell Sci.
116: 4401-4408
[Abstract]
[Full Text]
-
Padow, M., Lai, L., Deivanayagam, C., DeLucas, L. J., Weiss, R. B., Dunn, D. M., Wu, X., Kappes, J. C.
(2003). Replication of Chimeric Human Immunodeficiency Virus Type 1 (HIV-1) Containing HIV-2 Integrase (IN): Naturally Selected Mutations in IN Augment DNA Synthesis. J. Virol.
77: 11050-11059
[Abstract]
[Full Text]
-
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., Engelborghs, Y.
(2003). LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells. J. Biol. Chem.
278: 33528-33539
[Abstract]
[Full Text]
-
Woodward, C. L., Wang, Y., Dixon, W. J., Htun, H., Chow, S. A.
(2003). Subcellular Localization of Feline Immunodeficiency Virus Integrase and Mapping of Its Karyophilic Determinant. J. Virol.
77: 4516-4527
[Abstract]
[Full Text]
-
Fujita, M., Sakurai, A., Yoshida, A., Miyaura, M., Koyama, A. H., Sakai, K., Adachi, A.
(2002). Amino Acid Residues 88 and 89 in the Central Hydrophilic Region of Human Immunodeficiency Virus Type 1 Vif Are Critical for Viral Infectivity by Enhancing the Steady-State Expression of Vif. J. Virol.
77: 1626-1632
[Abstract]
[Full Text]
-
Limon, A., Devroe, E., Lu, R., Ghory, H. Z., Silver, P. A., Engelman, A.
(2002). Nuclear Localization of Human Immunodeficiency Virus Type 1 Preintegration Complexes (PICs): V165A and R166A Are Pleiotropic Integrase Mutants Primarily Defective for Integration, Not PIC Nuclear Import. J. Virol.
76: 10598-10607
[Abstract]
[Full Text]
-
Nymark-McMahon, M. H., Beliakova-Bethell, N. S., Darlix, J.-L., Le Grice, S. F. J., Sandmeyer, S. B.
(2002). Ty3 Integrase Is Required for Initiation of Reverse Transcription. J. Virol.
76: 2804-2816
[Abstract]
[Full Text]
-
Hooker, C. W., Lott, W. B., Harrich, D.
(2001). Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Target Distinct Phases of Early Reverse Transcription. J. Virol.
75: 3095-3104
[Abstract]
[Full Text]
-
Depienne, C., Mousnier, A., Leh, H., Le Rouzic, E., Dormont, D., Benichou, S., Dargemont, C.
(2001). Characterization of the Nuclear Import Pathway for HIV-1 Integrase. J. Biol. Chem.
276: 18102-18107
[Abstract]
[Full Text]